Pharma Pulse 4/9/24: AI in Clinical Development, Patient Preferences Play Essential Part in Contraceptive Care & more


The latest news for pharma industry insiders.

The State of AI in Clinical Development

In part 1 of this video interview with ACT editor Andy Studna, Stephen Pyke, chief clinical data and digital officer, Parexel, gives a broad overview of the use of artificial intelligence in clinical development and how regulatory bodies are viewing it.

Patient Preferences Play Essential Part in Contraceptive Care

Although there are medical considerations for patients with psychiatric conditions, prescribers must consider patient preference to increase adherence and effectiveness of contraception.

Is That AI Mammogram Worth the Cost?

The new add-on service for breast exams can cost between $40 and $100. We asked experts to separate the sales pitch from the science.

ViiV Healthcare announces U.S. FDA approval of Dovato(dolutegravir/lamivudine) for adolescents living with HIV

Dovato is now the first and only oral, two-drug, single-tablet regimen available for people aged 12 and older living with HIV, a population in need of additional treatment options

EVERSANA on LinkedIn:

Navigating healthcare journeys is complex, with adherence posing a significant challenge to patients' well-being. Maria Bucceri Kirsch shares hers insights on how manufacturers can harness the power of technology to overcome barriers and empower patients along the way in the most recent issue of Pharmaceutical Commerce Magazine:


Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs

© 2024 MJH Life Sciences

All rights reserved.